In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...
In this commentary, Michael J. Bloch, MD, writes about the epidemiological link between influenza infection and cardiovascular events and the potential benefits of influenza vaccination on cardiovascular...
In this commentary, Michael J. Bloch, MD writes about controversies in the effect of dietary cholesterol and egg consumption on cardiovascular events and mortality.
In this article, James Matera, DO, writes about a newer agent, finarenone, which is a nonsteroidal, selective mineralocorticoid receptor antagonist that can treat chronic kidney disease.
In this commentary, a team from Johns Hopkins Medicine writes about their experiences creating and implementing a digital health platform and explains how apps can contribute to improving patients’ health.
...
In this editorial by Consultant Board Member Dr Michael Bloch, he reflects on a 1961 Consultant article about cardiovascular disease management and how it has affected him.
Samantha Ellingson, PharmD, BCPS, and Timothy H. Self, PharmD—Series Editor
Samantha Ellingson, PharmD, BCPS, and Timothy H. Self, PharmD—Series Editor
When considering potential drug interactions with statin therapy, it is important to consider the hepatic pathways that could be negatively impacted with the addition of new medications.
In this commentary, Robert Rosenson, MD, explains that PCSK9 inhibitors may be a useful alternative therapy in lowering LDL cholesterol in individuals who are unable to tolerate statins at the doses...
